NextCure Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from NextCure Inc
Access all reports
NextCure Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomedicines to address cancer and other immune-related diseases by restoring normal immune function. The company's pipeline includes NC410, designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody targeting B7-H4, a protein found on various tumor types; and NC525, which targets LAIR-1 to eliminate AML blast cells and leukemic stem cells while sparing normal blood cells. NextCure's research also extends to preclinical evaluations of additional immunomodulatory molecules. NextCure is headquartered in Beltsville, Maryland, and its shares are listed on the Nasdaq.
Latest articles
Cristiano Amon: Qualcomm's 5G Specialist CEO
Cristiano Amon, Qualcomm CEO, has spent two decades at the company while taking on several roles, developing both technical and business expertise.
16 Sep 2024
Qualcomm: Quality Communication and Semiconductor Innovation
Founded in 1985, Qualcomm has transformed the digital communication industry with CDMA technology and its advanced semiconductor business.
13 Sep 2024
Strong Opinions, Loosely Held: Pontus Dackmo on Flexibility and Market Psychology
After a two-decade career in finance, Pontus Dackmo co-founded Protean Funds Scandinavia in 2022, where he now serves as CEO and Investment Manager.
4 Sep 2024
Ticker symbol
NXTC
Country
🇺🇸 United States